MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial

M Mrinal Gounder M Melissa Johnson (Sarah Cannon Research Institute, Nashville) R Rebecca S. Heist G Geoffrey I. Shapiro S Sophie Postel-Vinay F Frederick H. Wilson E Elena Garralda G Gerburg Wulf C Caroline Almon S Salah Nabhan E Elia Aguado-Fraile P Peng He (Department of Pathology, University of California San Francisco, San Francisco, CA, USA.) M Mathilde Romagnoli M Mohammad Hossain R Rohini Narayanaswamy (Agios Pharmaceuticals) A Amel Sadou-Dubourgnoux M Michael Cooper V Vasileios Askoxylakis H Howard A. Burris J Josep Tabernero (Vall d’Hebron Hospital Campus, Barcelona)

Article Details

Volume / Issue Vol. 16, Issue 1
Published January 06, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (20)

M

Mrinal Gounder

M

Melissa Johnson

Sarah Cannon Research Institute, Nashville

R

Rebecca S. Heist

G

Geoffrey I. Shapiro

S

Sophie Postel-Vinay

F

Frederick H. Wilson

E

Elena Garralda

G

Gerburg Wulf

C

Caroline Almon

S

Salah Nabhan

E

Elia Aguado-Fraile

P

Peng He

Department of Pathology, University of California San Francisco, San Francisco, CA, USA.

M

Mathilde Romagnoli

M

Mohammad Hossain

R

Rohini Narayanaswamy

Agios Pharmaceuticals

A

Amel Sadou-Dubourgnoux

M

Michael Cooper

V

Vasileios Askoxylakis

H

Howard A. Burris

J

Josep Tabernero

Vall d’Hebron Hospital Campus, Barcelona